Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases
Autor: | Cezary Szczylik, Anna Waśko-Grabowska, Jakub Żołnierek, Beata Obrocka, Paweł Nurzyński, Sylwia Oborska, Ewa Kuszatal, Przemysław Langiewicz |
---|---|
Rok vydání: | 2009 |
Předmět: |
Oncology
Compassionate Use Trials Male Cancer Research Indoles Pyridines urologic and male genital diseases Placebos Drug Delivery Systems Renal cell carcinoma Antineoplastic Combined Chemotherapy Protocols Sunitinib Medicine Randomized Controlled Trials as Topic Benzenesulfonates Bone metastasis General Medicine Middle Aged Sorafenib female genital diseases and pregnancy complications Kidney Neoplasms Treatment Outcome Disease Progression Female medicine.drug Adult Niacinamide medicine.medical_specialty Bone Neoplasms Clinical Trials Phase II as Topic Internal medicine Carcinoma Humans Pyrroles Carcinoma Renal Cell Aged Retrospective Studies business.industry Phenylurea Compounds Interferon-alpha Sunitinib malate medicine.disease digestive system diseases Surgery Clinical Trials Phase III as Topic business Kidney cancer Kidney disease |
Zdroj: | Scopus-Elsevier |
ISSN: | 1432-1335 |
Popis: | Introduction This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC). Methods The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w. Results Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047). Conclusion Further evaluation of the effect of these therapies on bone metastases in RCC is warranted. |
Databáze: | OpenAIRE |
Externí odkaz: |